(Q37254460)

19 August 2017

1 reference

title

Contrast medium-induced nephropathy: strategies for prevention (English)

1 reference

19 August 2017

1 reference

Anne Massicotte

1

1 reference

19 August 2017

language of work or name

English

0 references

publication date

1 September 2008

1 reference

19 August 2017

1 reference

19 August 2017

volume

28

1 reference

19 August 2017

issue

9

1 reference

19 August 2017

page(s)

1140-1150

1 reference

Contrast-induced nephropathy: a clinical and evidence-based approach

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.9.1140

Clinical practice. Preventing nephropathy induced by contrast medium

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.9.1140

Contrast-induced nephropathy: definition, epidemiology, and patients at risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.9.1140

Strategies to reduce the risk of contrast nephropathy: an evidence-based approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.9.1140

Contrast agent--associated nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.9.1140

Nephrotoxic effects of X-ray contrast media

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.9.1140

Concomitant drugs with exposure to contrast media

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.9.1140

Prevention of contrast-induced nephropathy with volume supplementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.9.1140

Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.9.1140

Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.9.1140

N-acetylcysteine for prevention of radiographic contrast material-induced nephropathy: is the intravenous route best?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.9.1140

Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.9.1140

Acetylcysteine for prevention of contrast nephropathy: meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.9.1140

Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.9.1140

Role of N-acetylcysteine in prevention of contrast-induced nephropathy after cardiovascular procedures: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.9.1140

Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.9.1140

Acetylcysteine for prevention of contrast-induced nephropathy after intravascular angiography: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.9.1140

N-acetylcysteine for the prevention of contrast-induced nephropathy. A systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.9.1140

N-acetylcysteine prophylaxis significantly reduces the risk of radiocontrast-induced nephropathy: comprehensive meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.9.1140

N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.9.1140

Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.9.1140

Systematic review of the impact of N-acetylcysteine on contrast nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.9.1140

N-acetylcysteine for the prevention of radiocontrast induced nephropathy: a meta-analysis of prospective controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.9.1140

Acetylcysteine and contrast agent-associated nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.9.1140

Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.9.1140

A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.9.1140

A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.9.1140

Prevention of contrast-induced nephropathy in vascular patients undergoing angiography: a randomized controlled trial of intravenous N-acetylcysteine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.9.1140

N-acetylcysteine and contrast-induced nephropathy in primary angioplasty.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.9.1140

21 January 2018

Identifiers

DOI

10.1592/PHCO.28.9.1140

1 reference

release_4wqdhtyjibdphn3lbeydyq74gi

19 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/4wqdhtyjibdphn3lbeydyq74gi

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference